[1]
|
A. H. Zargar, V. K. Gupta, A. I. Wani, S. R. Masoodi, M. I. Bashir, B. A. Laway, M. A. Ganie and M. Salahudin, “Prevalence of Ultrasonically Proved Polycystic Ovaries in North Indian Women with Type 2 Diabetes Mellitus,” Reproductive Biology & Endocrinology, Vol. 3, No. 35, 2005.
doi:10.1186/1477-7827-3-35
|
[2]
|
B. Dipankar, M. S. Kumar, M. Satinath, P. Mamata, “Clinical Correlation with Biochemical Status in Polycystic Ovary Syndrome,” Journal of Obstetrics & Ganecology of India, Vol. 55, No. 1, 2005, pp. 67-71.
|
[3]
|
P. Dabadgyhae, B. J. Robert, J. Wang, M. J. Davis and R. J. Norman, “Glucose Tolerance Abnormalities in Australian Women with Polycystic Ovary Syndrome,” MJA, Vol. 187, No. 6, 2007, pp. 328-331.
|
[4]
|
S. Jonard and D. Dewailly, “Follicular Excess in Polycystic Ovaries, Due to Intra Ovarian Hyperandrogenism May Be the Main Culprit for Follicular Arrest,” Human Reproduction Update, Vol. 10, No. 2, 2004, pp. 107-117.
doi:10.1093/humupd/dmh010
|
[5]
|
Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Work Shop Group; Revised 2003 Consensus on Diagnostic Criteria and Long Term Health Risk Related to PCOS, Fertil Steril, Vol. 81, No. 2004, pp. 19-25.
|
[6]
|
S. Franks, “Diagnosis of Polycystic Ovarian Syndrome in Defense of Rotterdam Criteria,” Journal of Clinical Endocrinology and Metabolism, Vol. 2, No. 3, 2005, pp. 786-789.
|
[7]
|
A. H. Alankash, “Polycystic Ovarian Syndrome: The Correlation between the LH:FSH and Disease Manifestations,” Middle East Fertility Society Journal, Vol. 12, No. 1, 2007, pp. 35-40.
|
[8]
|
R. A. Lobo and E. Carmina, “Importance of Diagnosing PCOS,” Annuals of Internal Medicine, Vol. 32, No. 2000, pp. 989-993.
|
[9]
|
E. A. Nager, PA-C and MMS, “Prompt Treatment Is Necessary to Control and Prevent Further Progression of Pcos Related Insulin Resistance, Dyslipidemia, Type 2 Diabetes, Cardiovascular Disease and Cancer,” Search Archives, Vol. 14, No. 1, 2006, p. 49.
|
[10]
|
D. A. Ehrmann, “Polycystic Ovary Syndrome,” The New England Journal of Medicine, Vol. 352, No. 2005, pp. 12223-12236. doi:10.1056/NEJMra041536
|
[11]
|
Polycystic Ovary Syndrome Writing Committee, “AACE Position Statement on Metabolic & CVS Consequences of Polycystic Ovary Syndrome,” Endocrine Practice, Vol. 11, No. 2, 2005, p. 125.
|
[12]
|
A. A. Nasr, H. Hamzah, Z. A. El Maaty, H. Gaber and O. Azzam, “Transvaginal Appearances of Ovary in Infertile Women with Oligomenorrhae: Association with Clinical & Endocrine Profile,” Middle East Fertility Society Journal, Vol. 9, No. 2, 2004, pp. 140-149.
|
[13]
|
K. E. Sharquie, A. Al-Bayatti, A. J. Al-Bahar and Q. M. A. Al-Zaidi, “Acanthosis Nigricans as Skin Manifestation of Polycystic Ovary Syndrome in Primary Infertile Females,” Middle East Fertility Society Journal, Vol. 9, No. 2, 2004, pp. 136-139.
|
[14]
|
F. Nazir, S. Sayeed, M. Malik, H. Aziz and S. A. S. Rana, “Polycystic Ovarian Syndrome—Diagnosis and Management in Fertility Deprivation,” Pakistan Journal of Obstetrics & Gynecology, Vol. 12, No. 1-2, 1999, pp. 59-71.
|
[15]
|
F. Haq, O. Aftab and J. Rizvi, “Clinical, Biochemical and Ultrasonic Features of Infertile Women with Polycystic Ovarian Syndrome,” J Coll Physicians Surg PAK, Vol. 17, No. 2, 2007, pp. 76-80.
|
[16]
|
F. Adil, H. Ansar and A. A. Munir, “Polycystic Ovarian Syndrome and Hyperinsulinemia,” Journal of Liaquat University of Medical and Health Sciences, Vol. 4, No. 3, 2005, pp. 89-93.
|
[17]
|
H. Hassa, H. M. Tanvir and Z. Yildiz, “Comparison of Clinical and Laboratory Characteristic of Cases with Polycystic Ovarian Syndrome Based on Rotterdam Criteria and Women with Only Clinical Signs Are Oligo/Anovolution or Hirsutism,” Archives of Gynecology and Obstetrics, Vol. 274, No. 4, 2006, pp. 227-232.
doi:10.1007/s00404-006-0173-8
|
[18]
|
A. Razak, A. Nadak and A. Tace, “Polycystic Ovarian Syndrome: The Correlation between the LH:FSH and Disease Manifestations,” Middle East Fertility Society Journal, Vol. 12, No. 1, 2007, pp. 35-40.
|